A daily stock analysis based on stock market today
  • Daily Roll
  • YouTube
  • Podcast
  • Investor Hubs
    • Starter Investors Hub
    • Dividend Seekers Hub
    • The Risk Hub
    • COVID-19 Investing Hub
  • Sign Up
  • Boot Camp

A Gene-editing Stock to Buy

6/28/2021

 

KEY POINTS

  • S&P and NASDAQ hit record highs as court rulings boost tech stocks.
  • Intellia Therapeutics (NTLA) announces breakthrough interim trial results
  • Editas Medicine (EDIT) gets pulled from the death spiral by gene-editing industry breakthroughs. Is it a dip worth buying?

OVERALL MARKET

S&P and NASDAQ hit record highs as court rulings boost tech stocks.
Picture
Today’s market closed with a mix of green and red. While the DOW dropped points for the day, the S&P and NASDAQ closed at record highs once again!

Interestingly, the tech sector is on the rise while cyclical sectors like energy and transportation are falling. Overall, investors are waiting for a few economic indicators later this week, including the monthly employment report to help economists analyze the nation’s progress. We'll discuss them once the reports are out.

GET THE DAILY MARKET RECAP

Did you know you can get your Daily Market recap report on YouTube, listen to it on our Podcast, or get it in your inbox?

Watch it, 
Listen to it,
Or, read it. 
 
Sign up for a free Stock Card account to get the report in your mailbox every day.
Give Stock Card A try!

WHAT'S UP?

Intellia Therapeutics (NTLA) Announces Breakthrough Interim Trial Results
The first gene-editing stock to discuss today is Intellia Therapeutics Inc (NTLA), up more than 50% today. This price jump is thanks to an important announcement regarding positive interim results for gene-editing trials on interior organs.

CEO John Leonard said that this breakthrough would allow them to expand their gene-editing capabilities to fight against genetic diseases. Standing at the edge of a new frontier in medical care, this seems like a company to keep an eye on as they continue to develop new approaches to genetic issues. 

I own a few shares, and I picked them up along nine other gene-editing stocks as a bet on the future of personalized medicine. I only wished I bought more when the gene-editing stocks lost some momentum earlier this year.

STOCK CARD COLLECTION

​Today, two gene-editing stocks grabbed my attention: Intellia Therapeutics Inc (NTLA) and Editas Medicine Inc (EDIT).

Last year, when Prof. Jennifer Doudna and her colleagues won the Nobel Prize for the discovery of CRISPR technology, we published the gene-editing collection on the Stock Card platform. You may have already seen it. Type in "genome (gene) editing" in the search bar, and you get the list of companies making progress in this rapidly-growing market.

>> Get the list of gene-editing stocks. 
​Gene-editing Stocks

WHAT'S DOWN?

Editas Medicine (EDIT) gets pulled from the death spiral by gene-editing industry breakthroughs. So is it a dip worth buying?
Riding the coattails of Intellia’s hype this week, Editas Medicine Inc (EDIT) also saw a jump in share price. However, Editas has had a rough year, stuck in a downward spiral since coming into the new year as high as $90/share.  Interestingly, Editas' co-founder Jennifer Doudna is the same professor who won the Nobel prize for discovering CRISPR. Although Jennifer quit Editas, the company is still among the leaders in the industry.

The main research program for this biotech company is EDIT-101, a treatment for hereditary blindness. Editas is also tackling sickle cell disease, and received FDA approval for children’s tests last week. 

EDIT follows closely behind its bigger brother Intellia (NTLA), we just discussed. It’s important to note that CRISPR and gene-editing technology is in their first innings, and there is so much more left to be done in this industry. For example, Intellia’s latest announcement that pushed the stock up 50% was only for a six-person sample. Much of this field is still open for development. If you want to benefit from the upside potential in this rapidly growing industry and feel comfortable with the inherent risk that comes with investing in innovation, consider Editas and other stocks from the gene-editing collection the next time you log in to research stocks on Stock Card. That's, indeed, what I plan to do this week. 

WANT THIS DAILY STOCK MARKET RECAP REPORT IN YOUR MAILBOX?

Sign up for a free account on Stock Card's website to get the daily market recap reports in your inbox:
Give Stock Card A Try!

Comments are closed.

    RSS Feed


    Archives

    December 2022
    September 2022
    July 2022
    February 2022
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    February 2021
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    January 2020
    October 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017

    Categories

    All
    Battle
    Education
    ETF Investing
    How To Invest
    New Podcast Episode
    New Portfolio
    Portfolio Update
    Starter 2020
    Stock Card VIP Pick
    Stock Lists
    The Daily Hype
    Update
    Watchlist Worthy
    Winners And Losers

© 2023 StockCard.io. All Rights Reserved.
​​
Disclaimer: StockCard.io is not, neither operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on StockCard.io and Stock Card Weekly represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The Stock Card team may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall StockCard.io be liable to any subscriber, visitor, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on StockCard.io, or relating to the use of, or inability to use, StockCard.io or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
  • Daily Roll
  • YouTube
  • Podcast
  • Investor Hubs
    • Starter Investors Hub
    • Dividend Seekers Hub
    • The Risk Hub
    • COVID-19 Investing Hub
  • Sign Up
  • Boot Camp